MANUFACTURING
Biologics to Open New Revenue Streams for Indian Pharma A
leader in generic drugs production, India has emerged as a ‘generic hub’ in recent years. Now, biotech-based drug development and production is also taking rooting in India. Generics Vs Biologics and hence the Biosimilars
Before diving into the ocean of Indian scenario for biologics, let’s get some basics right. The question which confuses people many a times is: are generics and biologics the same? And the answer is no, they are not the same. Let’s find out how. Biologics are basically the products which are developed and produced from living organisms like human, plant or animal cells and, of course, microorganisms (bacteria, yeast, etc.). Having no definite structure, biologics are large and complex molecules which undergo sophis-
48
P H A RM A F O C U S A S I A
ISSUE 45 - 2021
The Indian biologics market is expected to account for around US$12 billion by 2025 (a CAGR of 22 per cent) buoyed by its dominance in simple biologics including insulin, erythropoietin, monoclonal antibodies, drugs for cardiovascular and autoimmune diseases, etc. In this article, R B Smarta highlights some of the key elements that will play a defining role in driving this industry. R B Smarta, CMD-Interlink, Vice President (HADSA)
